Evolving Standards of HER2-Positive Breast Cancer

Article

Sunil Verma, MD, MSEd, FRCPC, discusses evolving standards of early stage HER2-positive breast cancer.

Clinical Pearls

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses evolving standards of early stage HER2-positive breast cancer.

  • The treatment of HER2-positive breast cancer has come a long way since the discovery that the addition of trastuzumab leads to improvement in disease-free and overall survival.
  • Moving forward, the focus should not be just on improving the endpoints of disease-free and overall survival, but also defining the patient population at the highest risk.
  • There remains a need to determine how patients can be treated better with less treatment.

<<<

Back to the 2014 Breast Cancer Symposium conference page

Recent Videos
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Related Content